Literature DB >> 17851241

Efficacy and tolerability of naltrexone in the treatment of alcohol dependence: oral versus injectable delivery.

Hendrik G Roozen1, Ranne de Waart, Wim van den Brink.   

Abstract

Oral naltrexone, an opioid antagonist, reduces relapse and heavy drinking in alcohol-dependent patients. However, oral delivery is associated with poor compliance and adverse events. To enhance treatment outcome and reduce side effects, injectable extended-release naltrexone formulations have been developed. Currently, there are no studies available directly comparing oral and injectable formulations of naltrexone in alcohol-dependent patients. This paper reviews the efficacy and adverse events of oral versus injectable extended-release naltrexone. Therefore, data were extracted from two recently published reviews about oral naltrexone in the treatment of alcohol dependence. Pooled outcomes were compared with reported outcomes of recent studies on injectable extended-release naltrexone. Injectable naltrexone seems to be effective in the management of alcohol dependence. Although inconclusive, the available results indicate that the expected advantages of injectable naltrexone over oral naltrexone still have to be proven. Randomized studies with direct comparisons of oral and injectable naltrexone are urgently needed.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17851241     DOI: 10.1159/000104882

Source DB:  PubMed          Journal:  Eur Addict Res        ISSN: 1022-6877            Impact factor:   3.015


  3 in total

1.  A Systematic Review of Naltrexone for Attenuating Alcohol Consumption in Women with Alcohol Use Disorders.

Authors:  Shantrel S Canidate; Giselle D Carnaby; Christa L Cook; Robert L Cook
Journal:  Alcohol Clin Exp Res       Date:  2017-02-03       Impact factor: 3.455

2.  Extended-release vs. oral naltrexone for alcohol dependence treatment in primary care (XON).

Authors:  Mia Malone; Ryan McDonald; Alex Vittitow; Jenny Chen; Rita Obi; Daniel Schatz; Babak Tofighi; Ann Garment; Andrea Kermack; Keith Goldfeld; Heather Gold; Eugene Laska; John Rotrosen; Joshua D Lee
Journal:  Contemp Clin Trials       Date:  2019-04-12       Impact factor: 2.226

Review 3.  Selective review and commentary on emerging pharmacotherapies for opioid addiction.

Authors:  Walter Ling; Larissa Mooney; Min Zhao; Suzanne Nielsen; Matthew Torrington; Karen Miotto
Journal:  Subst Abuse Rehabil       Date:  2011-10-28
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.